Surmodics gets IDE approval for drug-coated balloon; Adherium heralds data for its asthma-treating Smartinhaler;

> Surmodics ($SRDX) picked up the FDA's IDE approval for an early feasibility study of its SurVeil drug-coated balloon. Release

> Adherium presented new data on its Smartinhaler that showed increased adherence and a reduction in severe asthma attacks. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.